FRAXA's mission is to find effective treatments and a cure for all children and adults with Fragile X, by directly funding the most promising research. As the pace of Fragile X research accelerates, the prospects of finding effective treatments and a cure for Fragile X and autism continue to improve. FRAXA-funded researchers at universities around the world are leading the way.
FRAXA has Funded over $25 Million in New Biomedical Research
Each February 1, we receive 30-60 applications for postdoctoral fellowships and program grants. This is cutting-edge work! Browse funded research here.
FRAXA's research portfolio spans the spectrum of translational, pre-clinical, and clinical research -- all coordinated to make the most of each dollar. We maintain a diversified approach, developing several treatment strategies in parallel, since success is never certain when developing a single drug.
“Fragile X is poised to become a triumph for translational research and the design of rational therapeutics for brain disease.”
- Dr. Justin Fallon, FRAXA Scientific Advisor
- Mark Bear’s goal: disease-modifying treatments for fragile X
- Researchers in Belgium tackle Excitability in the Fragile X Brain
- A Neuron to Remember: Correcting Imbalances in Fragile X Syndrome
- Argentinean Researchers Patricia Cogram, PhD, and Paulina Carullo, MD, are identifying Biomarkers for Fragile X Syndrome
- Fulcrum Therapeutics Launched with $55 Million to Reactivate the Fragile X Gene
- Cornell University researcher looks to restore Fragile X protein in neurons